金吾财讯 | 默沙东(MRK)股价震荡下行，截至发稿，跌11.73%，报88.085美元，成交额11.31亿美元。2024年公司销售额为642亿美元，较2023年增长7%。这接近预期的640亿美元。每股收益为7.65美元，略高于预期的7.56美元。2024年第四季度，公司营收156.2亿美元，同比增长6.77%，预期为154.5亿美元；净利润37.43亿美元，去年同期录得亏损12.26亿美元；每股收益1.48美元，预期为1.55美元。业绩指引方面，公司预计2025年营收641亿美元-656亿美元，市场预期673.7亿美元。公司的两大收入产品是 HPV 疫苗 Gardasil 和抗癌药物 Keytruda。后者将于 2028 年面临专利到期。杰富瑞分析师在最近给客户的一份报告中表示，公司“处于劣势”，投资者对该公司长期战略缺乏明确性感到失望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.